Abstract
Summary
Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.
Introduction
This review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.
Methods
We conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.
Results
We reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1 year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269 days [weekly] and 134 to 208 days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).
Conclusion
Although patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal.
Similar content being viewed by others
References
Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656
Nairus J, Ahmadi S, Baker S et al (2000) Quantitative ultrasound: an indicator of osteoporosis in perimenopausal women. J Clin Densitom 3:141–147
Frost ML, Blake GM, Fogelman (2001) Changes in QUS and BMD measurements with antiresorptive therapy: a two-year longitudinal study. Calcif Tissue Int 69:138–146
Frost ML, Blake GM, Fogelman I (2001) Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res 16:406–416
Nelson DA, Molloy R, Kleerekoper M (1998) Prevalence of osteoporosis in women referred for bone density testing: utility of multiple skeletal sites. J Clin Densitom 1:5–11
Melton LJ III (1995) How many women have osteoporosis now? J Bone Miner Res 10:175–177
McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287
Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008
Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968
Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921
Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859–862
Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
Unson CG, Siccion E, Gaztambide J et al (2003) Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt) 12:1037–1045
International Society for Pharmacoeconomics and Outcomes Research. ISPOR Medication Compliance and Persistence Special Interest Group (MCP). Available at: http://www.ispor.org/sigs/medication.asp. Retrieved July 17, 2006
Burrell A, Wong P, Ollendorf D et al (2005) Defining compliance/adherence and persistence: ISPOR Special Interest Working Group. Value Health 8:A194–A195
Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10:42–45
Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813
Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928
Siris E, Harris S, Rosen C et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022
Lo JC, Pressman AR, Omar MA et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928
Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861
Sunyecz J, Gallagher R, MacCosbe P (2006) Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female patient 31:21–28
Ettinger M, Gallagher R, MacCosbe P (2006) Medication persistence with weekly vs. daily doses of oral bisphosphonates. Endocr Pract 12:522–528
Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460
Brankin E, Walker M, Lynch NO et al (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1258
Cramer JA, Lynch NO, Gaudin A-F et al (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686–1694
Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Res Med Opin 22:2383–2391
Cramer JA (1998) Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 4:1563–1568
Caspard H, Chan AK, Walker AM (2005) Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 27:1639–1646
Delmas PD, Adami S, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838–1846
Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310
Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886
Reginster JY, Felsenberg D, Cooper C et al (2006) A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 2006 17:159–166
Acknowledgement
J. Cramer has served as a speaker and consultant for GSK and Roche, and consultant for Merck. Dr. Gold has served as a speaker and consultant for Amgen, Eli Lilly, GSK, Merck, P&G, Roche, and Sanofi Aventis. Dr. Silverman has served as a speaker and consultant for Amgen, Eli Lilly, GSK, Merck, NPS, P&G, Roche, and Sanofi Aventis. Dr. Lewiecki has served as a speaker and consultant for Amgen, Eli Lilly, GSK, Merck, Novartis, P&G, Roche, Sanofi Aventis, Servier, and Wyeth. The authors acknowledge the assistance of Linda Gorman, PhD, of Envision Pharma, in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cramer, J.A., Gold, D.T., Silverman, S.L. et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18, 1023–1031 (2007). https://doi.org/10.1007/s00198-006-0322-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-006-0322-8